Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction
暂无分享,去创建一个
B. Pitt | F. Zannad | W. Remme | J. Neaton | F. Martinez | B. Roniker | R. Bittman | Steve Hurley | J. Kleiman | M. Gatlin
[1] A. Khand,et al. Prevalence and Incidence of Arrhythmias and Sudden Death in Heart Failure , 2002, Heart Failure Reviews.
[2] J. López-Sendón,et al. The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction , 2004, Cardiovascular Drugs and Therapy.
[3] U. Walter,et al. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition , 2003, Thrombosis and Haemostasis.
[4] Sidney Goldstein,et al. Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure , 2002, Circulation.
[5] J. Delyani,et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. , 2002, Endocrinology.
[6] K. Weber,et al. Aldosterone-induced inflammation in the rat heart : role of oxidative stress. , 2002, The American journal of pathology.
[7] K. Dickstein,et al. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.
[8] R. Weiss,et al. The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. , 2002, American journal of physiology. Heart and circulatory physiology.
[9] S. Rajagopalan,et al. Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis , 2002, Circulation.
[10] N. Reichek,et al. OR-53: Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy , 2002 .
[11] Ricardo Rocha,et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. , 2002, American journal of physiology. Heart and circulatory physiology.
[12] G. Ertl,et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. , 2002, Journal of the American College of Cardiology.
[13] J. Delyani,et al. Effect of a selective aldosterone receptor antagonist in myocardial infarction. , 2001, American journal of physiology. Heart and circulatory physiology.
[14] K. Yee,et al. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. , 2001, Journal of the American College of Cardiology.
[15] H. Dargie,et al. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.
[16] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[17] D G Altman,et al. Calculating the number needed to treat for trials where the outcome is time to an event , 1999, BMJ.
[18] A. Struthers,et al. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. , 1997, Cardiovascular research.
[19] J. Chesebro,et al. Mechanisms Determining Course and Outcome of Diabetic Patients Who Have Had Acute Myocardial Infarction , 1997, Annals of Internal Medicine.
[20] C. Lang,et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. , 1995, The American journal of cardiology.
[21] J H Shih,et al. Sample size calculation for complex clinical trials with survival endpoints. , 1995, Controlled clinical trials.
[22] W. Wang,et al. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. , 1994, Hypertension.
[23] S. Whitebread,et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. , 1987, The Journal of pharmacology and experimental therapeutics.
[24] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .